FRAMINGHAM, Mass.--(BUSINESS WIRE)--rEVO Biologics, an LFB Company, announced today that it has completed the treatment and follow up phase of a key dose ranging study of LR769, a novel recombinant ...
GTC Biotherapeutics (GTCB) Enters Agreements with LFB Biotechnologies for Funding of $12.3 Million with an Option for LFB to Fund an Additional $6.4 Million FRAMINGHAM, Mass.--(BUSINESS WIRE)--GTC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback